Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: A randomized, observer-blind, controlled Phase 3 study

Vaccine

Volumn 27, Issue 15, 2009, Pages 2188-2193

  Schuller, Elisabeth ^a   Klade, Christoph S ^a   Wölfl, Gabriele ^a   Kaltenböck, Astrid ^a   Dewasthaly, Shailesh ^a   Tauber, Erich ^a  

^a INTERCELL AG   (Austria)

Author keywords

IC51; Japanese encephalitis; Vaccination regimen

Indexed keywords

IC 51; INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; JAPANESE ENCEPHALITIS VACCINE IC51; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EPIDEMIC ENCEPHALITIS; FATIGUE; FEMALE; FLU LIKE SYNDROME; GERMANY; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IRELAND; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NORMAL HUMAN; PAIN; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUBJECT; SEROCONVERSION; SINGLE DRUG DOSE; SKIN INDURATION; SORE THROAT; THORAX PAIN; VACCINATION; VIRUS STRAIN; VOMITING;

ADULT; AGED; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; VACCINATION; VACCINES, INACTIVATED;

EID: 61549095001     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.12.062     Document Type: Article

References (19)

1. Burke D.S., and Leake C.J. Japanese encephalitis. In: Monath T.P. (Ed). The arboviruses: epidemiology and ecology, vol. III (1988), CRC Press, Boca Raton, FL 63-92
2. Vaughn D.W., and Hoke C.H. The epidemiology of Japanese encephalitis: prospects for prevention. Epidem Rev 14 (1992) 197-221
3. Igarashi A. Epidemiology and control of Japanese encephalitis. Wld Hlth Stats Quart 45 (1992) 299-305
4. Shlim D.R., and Solomon T. Japanese encephalitis vaccine for travellers: exploring the limits of risk. Clin Infect Dis 15 (2002) 183-188
5. Tauber E., Kollaritsch H., von Sonnenburg F., Lademann M., Jilma B., Firbas C., et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 198 (2008) 493-499
6. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 370 (2007) 1847-1853
7. Schuller E., Jilma B., Voicu V., Golor G., Kollaritsch H., Kaltenböck A., et al. Long-term Immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis vaccine IC51. Six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 26 34 (2008) 4382-4386
8. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 188 8 (2003) 1213-1230
9. Xin Y.Y., Ming Z.G., Peng G.Y., Jian A., and Min L.H. Safety of a live-attenuated Japanese encephalitis virus vaccine (SA14-14-2) for children. Am J Trop Med Hyg 39 2 (1988) 214-217
10. Liu Z.L., Hennessy S., Strom B.L., Tsai T.F., Wan C.M., Tang S.C., et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 176 5 (1997) 1366-1369
11. Sohn Y.M., Tandan J.B., Yoksan S., Ji M., and Ohrr H. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine 26 13 (2008) 1638-1643
12. Lyons A., Kanesa-thasan N., Kuschner R.A., Eckels K.H., Putnak R., Sun W., et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25 (2007) 3445-3453
13. Lehtinen V.A., Huhtamo E., Siikamaki H., and Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J Clin Virol 43 1 (2008) 93-95
14. Buhl M.R., Black F.T., Andersen P.L., and Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scand J Infect Dis 28 2 (1996) 189
15. Wittesjö B., Eitrem R., Niklasson B., Vene S., and Mangiafico J.A. Japanese encephalitis after a 10-day holiday in Bali. Lancet 345 8962 (1995) 856-857
16. Schöndorf I., Ternak G., Oroszlàn G., Nicolay U., Banzhoff A., and Zent O. Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., Days 0, 7, 21). Hum Vaccin 3 (2007) 42-47
17. Schöndorf I., Beran J., Cizkova D., Lesna V., Banzhoff A., and Zent O. Tick-borne encephalitis (TBE) vaccination: applying the most suitable vaccination schedule. Vaccine 25 (2007) 1470-1475
18. Zent O., and Bröker M. Tick-borne encephalitis vaccines: past and present. Expert Rev Vaccin 4 (2005) 747-755
19. Zent O., Jilg W., Plentz A., Schwarz T.F., Frühwein N., Kuhr H.B., et al. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule. Vaccine 21 (2003) 4655-4660